These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22138342)

  • 1. Does FDG PET-assisted management of patients with left ventricular dysfunction improve quality of life? A substudy of the PARR-2 trial.
    Shukla T; Nichol G; Wells G; deKemp RA; Davies RA; Haddad H; Duchesne L; Freeman M; Gulenchyn K; Racine N; Humen D; Benard F; Ruddy TD; Chow BJ; DaSilva J; Garrard L; Guo A; Chen L; Beanlands RS
    Can J Cardiol; 2012; 28(1):54-61. PubMed ID: 22138342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial.
    Abraham A; Nichol G; Williams KA; Guo A; deKemp RA; Garrard L; Davies RA; Duchesne L; Haddad H; Chow B; DaSilva J; Beanlands RS;
    J Nucl Med; 2010 Apr; 51(4):567-74. PubMed ID: 20237039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2).
    Beanlands RS; Nichol G; Huszti E; Humen D; Racine N; Freeman M; Gulenchyn KY; Garrard L; deKemp R; Guo A; Ruddy TD; Benard F; Lamy A; Iwanochko RM;
    J Am Coll Cardiol; 2007 Nov; 50(20):2002-12. PubMed ID: 17996568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Follow-Up of Outcomes With F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction Secondary to Coronary Disease.
    Mc Ardle B; Shukla T; Nichol G; deKemp RA; Bernick J; Guo A; Lim SP; Davies RA; Haddad H; Duchesne L; Hendry P; Masters R; Ross H; Freeman M; Gulenchyn K; Racine N; Humen D; Benard F; Ruddy TD; Chow BJ; Mielniczuk L; DaSilva JN; Garrard L; Wells GA; Beanlands RS;
    Circ Cardiovasc Imaging; 2016 Sep; 9(9):. PubMed ID: 27609816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial.
    D'Egidio G; Nichol G; Williams KA; Guo A; Garrard L; deKemp R; Ruddy TD; DaSilva J; Humen D; Gulenchyn KY; Freeman M; Racine N; Benard F; Hendry P; Beanlands RS;
    JACC Cardiovasc Imaging; 2009 Sep; 2(9):1060-8. PubMed ID: 19761983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function.
    Beanlands RS; Ruddy TD; deKemp RA; Iwanochko RM; Coates G; Freeman M; Nahmias C; Hendry P; Burns RJ; Lamy A; Mickleborough L; Kostuk W; Fallen E; Nichol G;
    J Am Coll Cardiol; 2002 Nov; 40(10):1735-43. PubMed ID: 12446055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods.
    Beanlands R; Nichol G; Ruddy TD; deKemp RA; Hendry P; Humen D; Racine N; Ross H; Benard F; Coates G; Iwanochko RM; Fallen E; Wells G;
    Control Clin Trials; 2003 Dec; 24(6):776-94. PubMed ID: 14662282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial (99m)Tc-MIBI SPECT and (18)F-FDG PET.
    Zhang X; Liu XJ; Wu Q; Shi R; Gao R; Liu Y; Hu S; Tian Y; Guo S; Fang W
    J Nucl Med; 2001 Aug; 42(8):1166-73. PubMed ID: 11483675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging.
    Beanlands RS; Hendry PJ; Masters RG; deKemp RA; Woodend K; Ruddy TD
    Circulation; 1998 Nov; 98(19 Suppl):II51-6. PubMed ID: 9852880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of contrast-enhanced MRI with (18)F-FDG PET/201Tl SPECT in dysfunctional myocardium: relation to early functional outcome after surgical revascularization in chronic ischemic heart disease.
    Wu YW; Tadamura E; Yamamuro M; Kanao S; Marui A; Tanabara K; Komeda M; Togashi K
    J Nucl Med; 2007 Jul; 48(7):1096-103. PubMed ID: 17607039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase analysis by gated F-18 FDG PET/CT for left ventricular dyssynchrony assessment: a comparison with gated Tc-99m sestamibi SPECT.
    Wang L; Wei HX; Yang MF; Guo J; Wang JF; Fang W; Wang YT
    Ann Nucl Med; 2013 May; 27(4):325-34. PubMed ID: 23371445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of left ventricular volumes, ejection fraction and mass. Comparison of model-based analysis of ECG-gated (⁹⁹m)Tc-SPECT and ¹⁸F-FDG-PET.
    Khorsand A; Gyöngyösi M; Sochor H; Maurer G; Karanikas G; Dudczak R; Schuster E; Porenta G; Graf S
    Nuklearmedizin; 2011; 50(1):9-14. PubMed ID: 21165540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction.
    Vitale GD; deKemp RA; Ruddy TD; Williams K; Beanlands RS
    J Nucl Med; 2001 Dec; 42(12):1730-6. PubMed ID: 11752067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scar imaging using multislice computed tomography versus metabolic imaging by F-18 FDG positron emission tomography: a pilot study.
    Dwivedi G; Al-Shehri H; deKemp RA; Ali I; Alghamdi AA; Klein R; Scullion A; Ruddy TD; Beanlands RS; Chow BJ
    Int J Cardiol; 2013 Sep; 168(2):739-45. PubMed ID: 23102604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium.
    Ling LF; Marwick TH; Flores DR; Jaber WA; Brunken RC; Cerqueira MD; Hachamovitch R
    Circ Cardiovasc Imaging; 2013 May; 6(3):363-72. PubMed ID: 23595888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET for detecting myocardial viability: validation of 3D data acquisition.
    Brogsitter C; Grüning T; Weise R; Wielepp P; Lindner O; Körfer R; Burchert W
    J Nucl Med; 2005 Jan; 46(1):19-24. PubMed ID: 15632028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic performance of quantitative PET tools for stratification of patients with ischemic cardiomyopathy undergoing myocardial viability assessment.
    Santana CA; Faber TL; Soler-Peter M; Sanyal R; Esteves FP; Ornelas M; Folks RD; Verdes L; Santana LF; Candell-Riera J; Garcia EV
    Nucl Med Commun; 2008 Nov; 29(11):970-81. PubMed ID: 18836375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of optimum periods between onset of suspected acute myocarditis and ¹⁸F-fluorodeoxyglucose positron emission tomography in the diagnosis of inflammatory left ventricular myocardium.
    Ozawa K; Funabashi N; Daimon M; Takaoka H; Takano H; Uehara M; Kobayashi Y
    Int J Cardiol; 2013 Nov; 169(3):196-200. PubMed ID: 24075573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation of system performance, quality control standards and adherence to international FDG-PET/CT imaging guidelines. A national survey of PET/CT operations in Austria.
    Rausch I; Bergmann H; Geist B; Schaffarich M; Hirtl A; Hacker M; Beyer T
    Nuklearmedizin; 2014; 53(6):242-8. PubMed ID: 25131649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.